VTT and GE Healthcare developing novel biomarkers to predict Alzheimer’s disease

28-Jun-2012

Scientists from VTT Technical Research Centre of Finland in collaboration with the University of Eastern Finland have recently discovered a serum biochemical signature which predicts progression to Alzheimer’s disease months or even years before the first symptoms of the disease occur. The goal of the new collaboration between VTT and GE Healthcare is to validate this biomarker in a large patient cohort as well as to discover novel biomarker candidates.

Early detection of prodromal AD is vital both for assessing the efficacy of potential AD therapeutic agents as well as new disease modifying therapies are most likely to be effective when initiated during the early stages of disease. The elucidation of early metabolic pathways associated with progression to Alzheimer’s disease may also help in identifying new therapeutic avenues.

In 2010 GE Healthcare entered into “biosignatures initiative” alliance with Janssen Pharmaceutica N.V. (Janssen) to develop diagnostic biosignatures for pre-symptomatic identification of AD. As part of this programme, VTT will apply serum metabolite profiling to validate their recently discovered biochemical signature, as well as to discover novel biomarker candidates predictive of progression to AD.

VTT’s research professor Matej Orešič said: “We are excited about the prospect of collaborating with GE Healthcare to accelerate its research programs and to further develop our biomarker towards a clinical assay applicable in healthcare setting. VTT has over the past years built unique metabolomics and systems biology platforms and acquired vast amount of knowledge on metabolic profiles and pathways in human health and disease, which allow us to identify disease-specific biochemical signatures and pathways. We believe that integration of metabolomics into the GE’s and Janssen’s biosignatures initiative will lead to better tools for early detection of AD and may also lead to better therapeutic options.”

VTT Technical Research Centre of Finland

Request information now

Recommend news PDF version / Print

Share on

Facts, background information, dossiers
  • Alzheimer's disease
More about VTT Technical Research Centre of
More about GE Healthcare
  • News

    GE Healthcare Forms Strategic Alliance with FUJIFILM in Life Sciences

    GE Healthcare, a unit of General Electric Company, announced that it has entered into a Strategic Alliance Agreement with FUJIFILM Corporation. Under the alliance, Fujifilm will develop, manufacture and supply advanced biomolecular imaging systems to GE Healthcare. The products will be sold ... more

    Tecan and GE Healthcare collaborate for high throughput process development

    Tecan and GE Healthcare are working together to bring increased quality and efficiency to process development. The collaboration between the two suppliers focuses on high throughput screening of protein purification conditions, using the combination of Tecan’s Freedom EVO® automated worksta ... more

    GE Healthcare completes acquisition of Whatman plc

    GE Healthcare, a unit of General Electric Company announced that it has completed the acquisition of Whatman plc, a global supplier of filtration products and technologies. The acquisition expands GE Healthcare's offering for life science research and biopharmaceutical manufacturing. GE H ... more

  • Events
    Webinar
    On-Demand

    Insights into Recent Developments in Protein A Chromatography

    Protein A-based chromatography is the primary method used to purify monoclonal antibodies (MAbs). Despite much discussion about the high purchase costs, protein A medium (resin) still is a cost-efficient alternative to most other purification techniques. Over the past decade, there has b ... more

    Webinar
    On-Demand

    How to Combine Protein Purification Techniques to Optimize Your Results

    Significant improvements in a chromatography workflow can be achieved with small changes and proactive choices. Before starting protein purification, it is important to define your requirements and objectives. These may include outlining the required purity, activity and the quantity of th ... more

    Webinar
    On-Demand

    The Future of Continuous Downstream Processing

    A conversation with Biogen Idec and GE Healthcare Life Sciences. The increasing pressures from global competition plus the need to reduce manufacturing costs are driving the biopharmaceutical industry to improve operational excellence in development and manufacturing. Continuous downstream ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE